SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

StarkNet is a permissionless decentralized Layer 2 (L2) validity rollup, built to allow Ethereum to scale via cryptographic protocols called STARKs, without compromising Ethereum’s core principles of decentralization, transparency, inclusivity and security. The StarkNet Token is needed to operate the ecosystem, maintain and secure it, decide on its values and strategic goals, and direct its evolution. This token will be required for (i) governance, (ii) payment of transaction fees on StarkNet, and (iii) participation in StarkNet’s consensus mechanism.

Starknet

STRK is drawing attention around Starknets Bitcoin DeFi and privacy push, including strkBTC and STRK20, alongside its post-quantum security narrative. Traders are pairing those themes with recent price and volume strength, while some remain cautious about token unlocks and volatility.

TOSHI

TOSHI is drawing attention around hopes for a recovery and a breakout from a prolonged trading range, with traders pointing to rising volume and repeated resistance tests. Bulls anticipate a short squeeze, while skeptics cite weak price action and warn that the token could keep falling; no specific catalyst is established.

C3.ai, Inc. engages in the provision of enterprise artificial intelligence software for digital transformation. It delivers the C3 AI suite for developing, deploying, and operating large-scale AI, predictive analytics, and Internet of Things applications in addition to a portfolio of turn-key AI applications. It operates through the following geographical segments: North America, Europe, The Middle East, and Africa, Asia Pacific, and Rest of World. The company was founded by Thomas M. Siebel, Patricia A. House and Stephen Maurice Ward, Jr. on January 8, 2009 and is headquartered in Redwood City, CA.

C3.ai Inc - Ordinary Shares - Class A

C3.ai Inc

C3.ai is drawing attention for a rising share price and a potential technical breakout, with traders watching resistance and speculating that high short interest could amplify the move. Some also mention buyout rumors, but those remain unconfirmed; others question whether the rally is supported by the companys fundamentals.

Aerodrome Finance is a next-generation AMM designed to serve as Base's central liquidity hub, combining a powerful liquidity incentive engine, vote-lock governance model, and friendly user experience. Aerodrome inherits the latest features from Velodrome V2.

Aerodrome Finance

AERO is drawing attention amid a rebound and anticipation of the AerodromeVelodrome merger and broader multi-chain rollout, which traders see as an expansion beyond Base with potential to increase liquidity and fee activity. Sentiment is largely bullish, though some traders question whether the move can hold and worry about a pullback or sell-the-news reaction.

NEAR Protocol is the blockchain for AI. A high-performance, AI-native platform built to power the next generation of decentralized applications and intelligent agents. It provides the infrastructure AI needs to transact, operate, and interact across Web2 and Web3. NEAR combines three core elements: User-Owned AI, which ensures agents act in users’ best interests; Intents and Chain Abstraction, which eliminate blockchain complexity for seamless, goal-driven transactions across chains; and a sharded blockchain architecture that delivers the scalability, speed, and low-cost execution needed for real-world AI and Web3 use. This integrated stack makes NEAR the foundation for building secure, user-owned, AI-native applications at internet scale.

Near

NEARs privacy-enabled perpetuals launch with Hyperliquid is a prominent catalyst, with traders linking it to the tokens sharp rally. The discussion is broadly bullish on NEARs AI-agent and cross-chain infrastructure, though some traders warn of a pullback after the rapid gains.

Hormel Foods Corp. engages in the manufacturing and marketing of branded food products. It operates through the following segments: Retail, Foodservice, and International. The Retail segment consists of the processing, marketing, and sale of food products sold predominantly in the retail market. The Foodservice segment includes the processing, marketing, and sale of food and nutritional products for foodservice, convenience store, and commercial customers. The International segment focuses on processing, marketing, and selling company products internationally. The company was founded by George A. Hormel in 1891 and is headquartered in Austin, MN.

Hormel Foods Corp.

Hormels lowered fiscal 2026 sales outlook and weak retail volumes are driving concern, with traders pointing to falling consumer demand and recent share-price lows. The debt-funded Brakebush acquisition and resulting credit-rating downgrades add to the debate over whether the deal can revive growth or increase financial pressure.

OpenAI

Reports that OpenAI confidentially filed for an IPO, alongside Sam Altmans indication that a public listing could come within roughly a year, are driving attention. Traders debate the potential listings timing and valuation, with skeptics citing heavy spending and intensifying competition while others anticipate strong investor demand.

TELUS Corp. is a telecommunications company, which engages in the provision of telecommunication services and products primarily for wireless and wireline voice and data. It operates through TELUS Technology Solutions (TTech) and Digitally-led Customer Experiences–TELUS International (DLCX) segments. The TTech segment includes network revenues and equipment sales arising from mobile technologies, data revenues, healthcare software and technology solutions, voice and other telecommunications services revenues, and equipment sales. The DLCX segment is composed of digital customer experience and digital-enablement transformation solutions, including artificial intelligence and content management solutions, provided by TELUS International. The company was founded on October 4, 1990 and is headquartered in Vancouver, Canada.

Telus Corp.

TELUS is drawing attention after a steep selloff tied to weak results, heavy debt concerns and a roughly 55% dividend cut intended to support deleveraging. Bearish traders question managements outlook and AI spending plans, while some investors argue the cut may strengthen the balance sheet and see the beaten-down shares as a potential value opportunity.

Keeta is a high-performance layer-1 blockchain designed to unify transactions across different blockchains and fiat payment systems, eliminating the need for costly intermediaries, reducing fees, and enabling near-instant settlements. With 400-millisecond transaction finality and the ability to process 10 million transactions per second, Keeta sets a new industry benchmark for speed and scalability.  Founded in 2022 and backed by Eric Schmidt, the former CEO of Google, Keeta has been engineered to meet the stringent regulatory and operational requirements of financial institutions. Its advanced on-chain compliance protocols, including KYC and AML, ensure security and regulatory adherence. Keeta’s architecture natively supports asset tokenization and digital identity, making it an ideal platform for stablecoins and real-world asset transfers.  By facilitating cross-chain transactions and interoperability with existing payment systems, Keeta bridges the gap between cryptocurrencies and fiat, enabling a secure, efficient, and compliant global financial ecosystem.

Keeta

Keeta Personals launch and rollout of fiat-payment features, including ACH access and Visa Direct/Bivo Cash integrations, have drawn attention to KTA. Bulls view the releases as a step toward real-world adoption, while skeptics say the price response and limited demonstrated network usage leave execution unproven.

T-Mobile US, Inc. engages in the provision of wireless communications services under the T-Mobile and MetroPCS brands. It offers postpaid and prepaid wireless voice, messaging and data services, and wholesale wireless services. The company was founded in 1994 and is headquartered in Bellevue, WA.

T-Mobile US Inc

SpaceXs spectrum acquisition and Starlink Mobile ambitions have driven a sharp selloff in T-Mobile and other wireless carriers, as traders weigh the prospect of a new competitor. The community is divided between viewing SpaceX as a long-term threat to carrier growth and calling the reaction an overreaction given the infrastructure and capacity needed to rival established networks.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Should You Buy PMV Pharmaceuticals, Inc. (PMVP) After Golden Cross?

When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?

PMV Pharma Raises $50.8 Million to Fuel Cancer Drug Push

PMV Pharmaceuticals reports 46% ORR in Phase 2 trial for ovarian cancer drug rezatapopt. NDA submission planned for Q1 2027.read more...

PMV Pharmaceuticals (PMVP) Upgraded to Buy: What Does It Mean for the Stock?

PMV Pharmaceuticals (PMVP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

PMV Pharmaceuticals (PMVP) Upgraded to Buy: Here's Why

PMV Pharmaceuticals (PMVP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

PMV Pharmaceuticals (PMVP) Loses 26% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

PMV Pharmaceuticals (PMVP) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Why PMV Pharmaceuticals, Inc. (PMVP) Faces Funding Concerns Despite Positive Trial Activity

Why PMV Pharmaceuticals, Inc. (PMVP) Faces Funding Concerns Despite Positive Trial Activity...

PMV Pharmaceuticals (PMVP) to Release Earnings on Friday

PMV Pharmaceuticals (NASDAQ:PMVP) will be releasing its Q1 2026 earnings before the market opens on Friday, May 8. (View Earnings Report at...

Short Interest in PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Increases By 48.3%

PMV Pharmaceuticals, Inc. (NASDAQ:PMVP - Get Free Report) was the recipient of a significant increase in short interest during the month of April. As of April 15th, there was short interest totaling 2,314,712 shares, an increase of 48.3% from the March 31st total of 1,560,810 shares. Approximately...

PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Sees Large Growth in Short Interest

PMV Pharmaceuticals, Inc. (NASDAQ:PMVP - Get Free Report) was the target of a large growth in short interest in the month of March. As of March 13th, there was short interest totaling 1,485,129...

PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Short Interest Update

PMV Pharmaceuticals, Inc. (NASDAQ:PMVP - Get Free Report) saw a large decline in short interest in the month of February. As of February 27th, there was short interest totaling 1,232,783 shares, a...

PMV Pharmaceuticals, Inc. is a precision oncology company, which engages in the discovery and development of small molecule, tumor-agnostic therapies targeting p53. The company was founded by Arnold J. Levine, David Henry Mac, and Thomas E. Shenk in March 2013 and is headquartered in Princeton, NJ.

PMV Pharmaceuticals Inc

Bearish Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Stocktwits

Stocktwits Polls

$PMVP nice onco spec name here at these low 1 levels for small position on promising cancer data for small pop. ER in nov, recent offering done at 1.2s and  data  readout in near future.

So Generous

$PMVP look forward to additional updates on rezatapopt later this year. Initial approval likely in ovarian but would love to see expansion into other tumors.

$PMVP recent movement has been excellent, but anyone with insight on the dilution/warrant ramification upon NDA for rezatapopt? Significant dilution could mean this would go down?

$PMVP thanks, guys. I'm out. 
 
 Didn't have enough invested to make much if it runs, but felt good not to be in red anymore.

Alice In Dollarland

$PMVP institutional positioning? Bought some weeks ago for asymmetrical opportunity and seems to be getting some traction last days

Dutchie

$PMVP Dr. Eckler joins the Board following completion of enrollment in the Phase 2 monotherapy portion of the ongoing PYNNACLE Phase 2 pivotal clinical trial and as the Company prepares to submit a New Drug Application (NDA) for accelerated approval for rezatapopt in patients with platinum-resistant/refractory ovarian cancer with a TP53 Y220C mutation in the first quarter of 2027.

Dr. Eckler is a Principal at Samsara BioCapital where he leads the firm’s public equity strategy. Before joining Samsara in 2025, he held investment roles at ArrowMark Partners, and GMT Capital, and served as Vice President and Senior Biotech Analyst at RBC Capital Markets. Earlier in his career, he conducted research on the genetics of early brain development and circuit-level plasticity.

Venice

$PMVP  I believe this will run bids are stacked  I took a position and idk wtf company this is and idc lol

Feed

News

Sentiment

Earnings

Fundamentals

Info

PMVP PMV Pharmaceuticals Inc

Fundamentals

Latest PMVP News